Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 22, Number 3—March 2016

Online Report

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

Jennifer FurinComments to Author , Grania Brigden, Erica Lessem, Michael Rich, Laura Vaughan, and Sharonann Lynch
Author affiliations: Harvard Medical School, Boston, Massachusettes, USA (J. Furin); Médecins Sans Frontières Access Campaign, Geneva, Switzerland (G. Brigden, S. Lynch); Treatment Action Group, New York, NY, USA (E. Lessem); Brigham and Women’s Hospital, Boston (M. Rich); Partners In Health, Boston (M. Rich, L. Vaughan)

Main Article

Table 5

Progress in achieving targets set in global call to action for the programmatic use of bedaquiline and delamanid to treat multidrug-resistant tuberculosis

Target Status
500 Patients on BDQ by July 2015 1,258 patients by October 1, 2015
500 Patients on DLM by Jan 2016 >100 patients by October 1, 2015
TA given to 25 countries by 2016
Ongoing, already provided in 21 countries
BDQ and DLM routinely used by 20 countries by end of 2016 BDQ: 9 countries plus European Union by October 1, 2015; additional 20 by the mid-2016

DLM: 2 countries plus European Union by October 1, 2015; plans for other countries expected to be discussed in December 2015
BDQ and DLM dossiers submitted for registration in 25 countries by beginning of 2016 BDQ: 26 countries by October 1, 2015
DLM: 3 countries by October 1 2015

*BDQ, bedaquiline; DLM, delamanid.

Main Article